Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
Appointed director
PhaseBio Pharmaceuticals Inc (PHAS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/12/2022 8-K Quarterly results
Docs: "PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights",
"Corporate Overview August 2022"
05/16/2022 8-K Quarterly results
03/24/2022 8-K Quarterly results
Docs: "PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights",
"Corporate Overview March 24, 2022"
11/10/2021 8-K Quarterly results
Docs: "Corporate Overview November 2021"
08/12/2021 8-K Quarterly results
Docs: "PhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business Highlights",
"Corporate Presentation",
"PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of a BLA submission for Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor First 143 patients enrolled in the pivotal Phase 3 trial, with top-line results from interim analysis expected later this year"
11/12/2020 8-K Quarterly results
Docs: "PhaseBio Reports Recent Business Highlights and Third-Quarter 2020 Financial Results Expanded pivotal Phase 3 REVERSE-IT trial of product candidate bentracimab for reversal of antiplatelet effects of ticagrelor into Canada and dosed first patients outside the United States",
"Corporate Presentation"
08/11/2020 8-K Quarterly results
05/12/2020 8-K Quarterly results
03/30/2020 8-K Quarterly results
Docs: "PhaseBio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Recent Business Highlights Recently Initiated PB2452 Phase 3 Trial for the Reversal of the Antiplatelet Effects of Ticagrelor Received FDA Breakthrough Therapy Designation and EMA Prime Designation for PB2452 Secured PB2452 Financing and Co-Development Collaboration with SFJ Pharmaceuticals ® Malvern, PA and San Diego, CA, March 30, 2020 - PhaseBio Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2019, and provided an update on corporate activities. “Over the past year, PhaseBio has made tremendous progress ...",
"Corporate Overview March 2020"
11/14/2019 8-K Quarterly results
08/13/2019 8-K Quarterly results
Docs: "Reported positive preliminary PB2452 Phase 2a results: In June 2019, PhaseBio announced positive preliminary results from the Phase 2a trial of PB2452 for the reversal of the antiplatelet activity of ticagrelor in older and elderly subjects. This is the first trial of PB2452 to include older and elderly subjects on dual antiplatelet therapy of ticagrelor and low-dose aspirin. Subjects in the trial resemble the patient population most likely to be treated with ticagrelor and potentially to benefit from PB2452, if approved. In the trial, statistically significant reversal of ticagrelor was achieved within 5 minutes of initiation of PB2452 infusion and sustained for over 20 hours. Platelet function was normalized by 15 minutes following initiation of PB2452 infusion and remained in the normal..."
05/09/2019 8-K Quarterly results
Docs: "Completed underwritten public offering of common stock: In April 2019, PhaseBio closed an underwritten public offering of 4.1 million shares of its common stock at a price to the public of $12.00 per share, including shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. PhaseBio received $46.2 million in net proceeds, after deducting underwriting discounts and commissions and offering expenses. • PB1023 licensing deal: In April 2019, PhaseBio announced it licensed to ImmunoForge, Co. Ltd. the global rights for PB1023, a long-acting, ELP-based GLP-1 agonist. Under the terms of the agreement, PhaseBio granted ImmunoForge an exclusive, worldwide license, with rights to sublicense, to PB1023 for the development and commercialization of trea...",
"Corporate Presentation"
03/26/2019 8-K Quarterly results
Docs: "Reported PB2452 Phase 1 results: In March 2019, full results from the Phase 1 clinical trial of PB2452 were published online in the New England Journal of Medicine in a paper titled, “An Antibody-Based Ticagrelor Reversal Agent in Normal Volunteers” and simultaneously presented in a featured clinical research session at the American College of Cardiology’s 68th Annual Scientific Session. Results demonstrated PB2452 provided immediate and sustained reversal of the antiplatelet activity of ticagrelor. • Secured up to $15.0 million term loan facility: In March 2019, PhaseBio entered into a $15.0 million term loan facility with Silicon Valley Bank and WestRiver Innovation Lending Fund. PhaseBio received an initial tranche of $7.5 million upon execution of the loan agreement and will use...",
"PhaseBio Announces Term Loan of up to $15 Million Entered into term loan facility with Silicon Valley Bank and WestRiver Innovation Lending Fund to borrow up to $15 million",
"Corporate Presentation"
11/29/2018 8-K Quarterly results
Docs: "PhaseBio Pharmaceuticals, Inc. Condensed Statements of Operations Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017",
"About Pulmonary Arterial Hypertension Pulmonary arterial hypertension is a progressive and life-threatening orphan disease caused by abnormal constriction and adverse remodeling of the arteries in the lungs, leading to chronically elevated blood pressure in the pulmonary arteries. This increased pressure restricts blood circulation through the lungs, resulting in poor oxygenation, abnormal strain on the heart’s right ventricle and underfilling of the left ventricle. Over time, the remodeling worsens as inflammatory cells are recruited. This leads to tissue scarring and fibrosis, which results in severe restriction of blood flow, increasing the risk of developing life-threatening blood clots, heart failure and premature death. None of the approved treatment options is curative and long-term..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy